newsfilter
← Latest News
GlobeNewswire·

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage